Recent ALZN News
- Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo • Business Wire • 12/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2024 09:30:29 PM
- Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs • Business Wire • 12/12/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/11/2024 09:30:34 PM
- Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice • Business Wire • 11/19/2024 01:00:00 PM
- Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s • Business Wire • 10/16/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 08:30:38 PM
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards • Business Wire • 10/15/2024 12:00:00 PM
- Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference • Business Wire • 10/10/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/03/2024 08:40:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:30:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/11/2024 08:30:38 PM
- Alzamend Neuro Issues Letter to Stockholders • Business Wire • 08/26/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder • Business Wire • 08/19/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder • Business Wire • 08/12/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder • Business Wire • 08/06/2024 12:00:00 PM
- Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease • Business Wire • 08/05/2024 01:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:30:22 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 07/31/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/30/2024 08:30:39 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/30/2024 10:00:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:30:23 PM
- Alzamend Neuro Announces Reverse Stock Split • Business Wire • 07/12/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/10/2024 12:52:03 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/10/2024 04:15:12 AM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM